Page last updated: 2024-12-07

quinoxaline-2-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Quinoxaline-2-carboxylic acid is a heterocyclic compound that has been studied for its potential biological activities. It is a derivative of quinoxaline, a nitrogen-containing heterocyclic ring system found in many natural products and pharmaceuticals. Quinoxaline-2-carboxylic acid has shown promising activity as an anti-inflammatory agent, and its derivatives have been investigated as potential anticancer agents. The compound has also been explored as a building block in the synthesis of other heterocyclic compounds with potential biological applications.'

Cross-References

ID SourceID
PubMed CID96695
CHEMBL ID151797
SCHEMBL ID354679
MeSH IDM0124765

Synonyms (44)

Synonym
AC-2651
EN300-12790
quinoxaline-2-carboxylic acid ,
NCIOPEN2_001193
smr000068509
MLS000056026
nsc-86873
2-quinoxalinecarboxylic acid
879-65-2
nsc86873
EU-0066606
2-quinoxalinecarboxylic acid, 97%
Q0081
CHEMBL151797 ,
AKOS000270312
VU0118494-2
EC-000.2271
F2158-0310
2-quinoxalinecarboxylicacid
C18624
unii-m5oe8sn42m
nsc 86873
m5oe8sn42m ,
2-qca
HMS2379P19
2-carboxyquinoxaline
FT-0687559
FT-0602831
AM20070439
CL1016
SCHEMBL354679
AS-5295
SY002404
mfcd00012334
2-quinoxaline carboxylic acid
quinoxaline carboxylic acid
UPUZGXILYFKSGE-UHFFFAOYSA-N
W-204001
DTXSID80236688
CS-W002071
BBL104226
STL558240
Q27283516
bdbm50518654

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Thirty-five healthy adult pigs were randomly divided into seven groups and orally treated with Cyx at a dosage of 20 mg/kg of body weight for five consecutive days."( Tissue deposition and residue depletion of cyadox and its three major metabolites in pigs after oral administration.
Ding, H; Fang, B; Gu, X; Li, Y; Yang, F; Zeng, Z; Zhang, B; Zhao, N, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency6.30960.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency6.30960.025120.237639.8107AID886
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency19.95260.631035.7641100.0000AID504339
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency10.00000.28189.721235.4813AID2326
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency35.48130.006026.168889.1251AID540317
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency22.38720.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein skinhead-1Caenorhabditis elegansIC50 (µMol)100.00007.390021.523843.9000AID624474
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)320.00000.00011.076810.0000AID1575185
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1575185Inhibition of HIV1 reverse transcriptase assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 30 mins by scintillation counting method2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Multiple weak intercalation as a strategy for the inhibition of polymerases.
AID1848086Antimycobacterial activity against Mycobacterium bovis BCG Pasteur ATCC35734 assessed as inhibition of bacterial growth incubated for 5 days by broth microdilution method2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
AID102219Minimum inhibitory concentration against MAC NJ211 using Middlebrook 7H9 with glycerol and OADC enrichment2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
AID138703Minimum inhibitory concentration against Mtb H37Ra using Middlebrook 7H9 with glycerol and OADC enrichment2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (4.76)18.7374
1990's1 (2.38)18.2507
2000's10 (23.81)29.6817
2010's24 (57.14)24.3611
2020's5 (11.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.44 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index5.66 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.22%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (97.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]